1874-2858/20 Send Orders for Reprints to reprints@benthamscience.net



The Open Microbiology Journal

Content list available at: https://openmicrobiologyjournal.com

RESEARCH ARTICLE

DNA Sequence Analysis of BlaVEB Gene Encoding Multi-drug Resistant and Extended-spectrum β-lactamases Producer Isolates of *Enterobacteriaceae* and *Pseudomonas aeruginosa*

Mushtak T.S. Al-Ouqaili[1,*], Eman Khalaf[2] and Shaymaa H. Al-Kubaisy[3]

[1]*Department of Microbiology, University Of Anbar College of Medicine, Ramadi, 07830014212, Anbar Governorate, Ramadi, Iraq*
[2]*Department of Biology, College of Education for Pure Sciences, University of Anbar, Ramadi, 07822067907, Anbar Governorate, Ramadi, Iraq*
[3]*Department of Clinical laboratory Sciences, University of Anbar, College of Pharmacy, Ramadi, 07905584293, Anbar Governorate, Ramadi, Iraq*

Abstract:

Objective:

Multi-drug resistance Gram-negative bacteria possessing Extended-Spectrum β-Lactamase (ESBL) genes are of concern because of their resistance to third-generation cephalosporins. This study aims to investigate the molecular basis of resistance to modern β-lactams by ESBLs encoded by the bla_{VEB} gene and the gene's role in resistance. Also, gene sequencing was used to compare genetic similarities with global isolates using phylogenetic and cluster analyses.

Methods:

Between March and July 2018, a total of 100 Iraqi clinical isolates were examined, in this cross-sectional study, to determine their ESBL status using the double-disc synergy technique. Polymerase Chain Reactions (PCRs) were performed on extracted bla_{VEB} genes and sequencing of the target PCR products was performed. All bla_{VEB} sequences were compared with the available sequence data, using BLAST searches against the GenBank database.

Results:

A total of 35 isolates, comprising 5 *Escherichia coli*, 18 *Klebsiella pneumoniae*, and 12 *Pseudomonas aeruginosa* isolates were confirmed to possess ESBLs; the bla_{VEB} gene was detected in one isolate of each species. The sequencing of these genes revealed 99% similarity with the global standard genes deposited in GenBank.

Conclusion:

The bla_{VEB} gene plays an essential role in the resistance of ESBL-producing isolates to new β-lactams. Further, the sequencing and phylogenetic analyses of the genes from the *P. aeruginosa*, *K. pneumonia*, and *E. coli* isolates revealed 99% similarity with the GenBank global standard genes.

Keywords: Extended-spectrum beta-lactamase, VEB gene, PCR, DNA Sequence, GenBank, BLAST.

Article History	Received: August 15, 2019	Revised: October 18, 2019	Accepted: October 20, 2019

1. INTRODUCTION

Clinically, the most important β-lactam resistance mechanism operating in Gram-negative pathogens is enzymatic antibiotic inactivation by β-lactamases [1]. Extended-spectrum β-lactamase (ESBL)-mediated resistance has become prevalent, worldwide, resulting in Gram-negative bacteria being able to utilize these plasmid-encoded enzymes to hydrolyze the extended-spectrum cephalosporins (e.g., ceftazidime and cefotaxime) [2, 3]Evolutionary pressure has resulted in approximately 1000 different types of β-lactamases that are able to hydrolyze the β-lactam ring of susceptible antibiotics [4]. The plasmids that normally carry these resistance genes play important roles in the transfer of resistance between bacteria, increasing the breadth of the resistance to these and other antibiotics, like gentamicin. Thus, the therapeutic choices available for combatting resistant bacteria remain limited [5].

Among ESBLs, the most widespread and clinically

* Address correspondence to this author at: Department of Microbiology, College of Medicine, Anbar Governorate, Ramadi, Iraq; Tel: +964 07830014212;
E-mail: ph.dr.mushtak_72@uoanbar.edu.iq

relevant classes are the TEM, SHV, and CTX-M types. The TEM and SHV types are derived from the TEM-1, TEM-2, and SHV-1 penicillinases [6]. Other plasmid-mediated ESBLs, such as PER, VEB, GES, and IBC β-lactamases, have been described but are uncommon and have been found mainly in *Pseudomonas aeruginosa* and at a limited number of geographic sites [7]. The bla_{VEB} group is one of the smaller subsets of the class A β-lactamases. The bla_{VEB} enzymes appear to be frequently observed in non-fermenting species such as *P. aeruginosa*, *Acinetobacter baumannii*, and other Enter-obacter-iaceae spp., and their rate of proliferation is increasing [8]. This study characterized ESBL-producing Gram-negative bacteria, isolated in Iraq, using primary screening tests and confirmatory phenotypic analyses. Further, the bla_{VEB} genes encoding the ESBLs were detected, sequenced, and compared with other global isolates.

2. MATERIALS AND METHODS

Between March and July 2018, Gram-negative isolates were collected from patients attending the Al-Karkh General Hospital (Baghdad, Iraq). In this cross-sectional study, the bacteria were isolated from patients with burn wounds, non-burn wounds, otitis media, and urinary tract infections. Patient information (sex, age, duration of hospitalization, disease characteristics, type of therapy) was recorded. The bacterial isolates were identified using their morphological and biochemical characteristics. This study was conducted accor-ding to the principles of the Declaration of Helsinki; the nature of the study did not require having the patients provide informed consent as there were no patient manipulations involved in the study.

2.1. Preservation and Maintenance of Bacterial Isolates.

Isolates of *P. aeruginosa*, *Escherichia coli*, and *Klebsiella pneumoniae* were derived from patient samples. Bacterial isolates were stored, in a brain heart infusion broth containing 20% glycerol,[9] at -20°C for 6–8 months [9]. Prior to use in susceptibility tests, the bacterial isolates were grown and adjusted to a density equivalent to a 0.5 McFarland Standard [10].

2.1.1. Antimicrobial susceptibility testing

The susceptibilities of the collected isolates to ceftriaxone (30 µg), ceftazidime (30 µg), imipenem (10 µg), meropenem (10 µg), cefoxitin (30 µg), aztreonam (10 µg), and cefepime (30 µg) were determined using the disc diffusion method, as recommended by the Clinical and Laboratory Standards Institute (CLSI) [9].

2.2. Detection of ESBLs

2.2.1. Primary ESBL screening technique

The Kirby-Bauer disc diffusion technique was used to conduct primary ESBL screening. Briefly, this method entails the preparation of a suspension of the target bacteria at a standardized density. The bacterial suspension is used to swab the surface of Mueller-Hinton agar plates, after which antibiotic-impregnated discs were aseptically placed on the agar surface and the bacteria were allowed to grow for 18 h. Thereafter, the resultant zones of inhibition were measured and interpreted, according to CLSI guidelines [9].

2.2.2. Confirmatory ESBL test

In this test, one Amoxiclav (amoxicillin (30 µg) + clavulanic acid (10 µg) disc and one ceftazidime disc (30 µg) were placed on target bacteria-seeded agar plates, 10 mm apart. Amoxiclav and cefotaxime (30 µg) discs were also placed on the same agar plate, the same distance apart. The plates were incubated at 37°C for 16-18 h. An isolate was considered to produce an ESBL if the zone of inhibition around the antibiotic test disc was increased nearer the Amoxiclav disc, according to CLSI [9].

2.3. DNA Extraction

An automatic nucleic acid extraction system (SaMag-12, Sacace Biotechnologies, Como, Italy) was used to extract the genomic DNA from study isolates. For each bacterial isolate, colonies were grown on agar plates, suspended in brain heart infusion broth, and processed according to the manufacturer's instructions.

2.4. Molecular Technique for the Detection of ESBLs

Isolated genomic DNA samples were used as templates for specific Polymerase Chain Reaction (PCR) amplification and detection of the bla_{VEB} gene. Specifically, the bla_{VEB} forward (5'-CGACTTCCATTTCCCGATGC-3') and reverse (5'-GGACTCTGCAACAAATACGC-3') primers were used in conjunction with Maxime PCR Pre-Mix kits (Intron Biotechnologies, Seongnam, Korea). The optimum conditions for detection of the bla_{VEB} gene included initial denaturation at 95°C for 3 min followed by 30 cycles each, of denaturation (95°C for 45 s), annealing (50°C for 45 s), and amplification (72°C for 45 s); a final extension step (72°C for 7 min) completed the reaction. Agarose gel electrophoresis was performed to determine DNA amplicon sizes after extraction; standard DNA ladders were used to determine the size of the DNA bands [11]. The electrophoresis proceeded at 5 V/cm^2, in TBE buffer, for 1.5 h. When electrophoresis was completed, each gel was read using ultraviolet light (336 nm).

2.5. DNA Sequencing

Sequencing of the target PCR products was performed by the National Instrumentation Center for Environmental Management (Seoul, Korea). All the bla_{VEB} sequences were compared with the available sequence data, using BLAST searches, against the GenBank database (National Center for Biotechnology Information, Bethesda, MD, USA) to identify the sequences. Multiple sequence alignment was manually performed with closely related reference sequences from other *E. coli*, *K. pneumonia*, and *P. aeruginosa* isolates, available in GenBank, using the BLAST (http://www.ncbi.nlm.nih.gov) and BioEdit (Ibis Therapeutics, Carlsbad, CA, USA) programs. A neighbor-joining tree with combined bla_{VEB} data was constructed, according to maximum likelihood method, using Molecular Evolutionary Genetics Analysis (MEGA) 7 software (ver. 7, Pennsylvania State University, State College, PA,

USA) [12].

2.6. Statistical Analysis

The data were analyzed using Excel (Microsoft, Redmond, WA, USA), Minitab (ver. 17, Minitab, State College, PA, USA), and SPSS (ver. 24, IBM, Armonk, NY, USA). The Chi-square test was used to investigate the association between antibiotic susceptibility (sensitivity, resistance, intermediate), ESBL production, and bla_{VEB} gene prevalence among the bacterial isolates; P-values < 0.05 were considered statistically significant.

3. RESULTS

A total of 100 clinical specimens were collected during this study. Among these specimens, 65 were culture-positive for Gram-negative bacteria, 12 for Gram-positive bacteria, and 23 were culture negative. Gram-negative bacteria were isolated from the sites listed in Table **1**.

These isolates, screened using the Kirby-Bauer disc diffusion method, showed 21 (72.4%) *P. aeruginosa* isolates were resistant to ceftriaxone, 19 (65.5%) to ceftazidime, 7 (24.1%) to aztreonam, 13 (44.8%) to cefepime, 29 (100%) to cefoxitin and 1 (3.4%) to imipenem. The *K. pneumoniae* isolates were resistant to ceftriaxone 24 (92.3%), ceftazidime 23 (88.4%), aztreonam 21 (80.7%), and cefepime 12 (46.2%). The *E. coli* isolates demonstrated resistance to ceftriaxone 10(100%), ceftazidime 9 (90%), aztreonam 10 (100%), cefoxitin 10 (100%), meropenem 2 (20%), and imipenem 3 (30%).

Based on the confirmatory testing for the extended-spectrum β-lactamase production, 35 isolates were considered to produce ESBLs, including 12 (34%) *P. aeruginosa*, 18 (51%) *K. pneumoniae*, and 5 (14%) *E. coli* isolates.

PCR was then used to detect the presence of the bla_{VEB} gene in the *K. pneumoniae, E. coli*, and *P. aeruginosa* clinical isolates. Three isolates, one from each of the three species, were positive for the presence of bla_{VEB}.

3.1. Sequencing and Phylogenetic Analysis

Among the isolates, 3 possessed the bla_{VEB} gene and were sent for sequencing and phylogenetic analysis Fig. (**1**). The alignment study of the bla_{VEB} gene in *K. pneumoniae* revealed a genotype similar to other strains, from Australia, China, Brazil, Greece, and Tunisia, deposited in the GenBank (accession numbers documented in Table **2** and Fig. (**2**). Sequencing of the gene demonstrated 99% compatibility with the global standard gene in Gen Bank.

Table 1. Collected Gram-negative bacterial specimens, including their sites of collection.

Bacteria	Burn Woundsn (%)	Non-Burn Woundsn (%)	Urinary Tractn (%)	Otitis Media (%)	No. of Isolates n (%)
K. pneumoniae	20 (77%)	–	5 (19%)	1 (4%)	26 (40%)
P. aeruginosa	18 (62%)	2 (7%)	–	9 (31%)	29 (45%)
E. coli	4 (40%)	–	6 (60%)	–	10 (15%)
–	–	–	–	–	**65**

Table 2. BLAST results comparing the bla_{VEB} gene from the *Klebsiella pneumoniae, Pseudomonas aeruginosa,* and *Escherichia coli* isolated in this study with those deposited in GenBank.

Isolate	Accession	Country	Similarity
K. pneumoniae	ID: CP031802.1	Australia	99%
–	ID: MF417536.1	Brazil	99%
–	ID: KY630495.1	Brazil	99%
–	ID: CP006657.1	China	99%
–	ID: JN406319.1	Greece	99%
–	ID: KP007363.1	Tunisia	99%
P. aeruginosa	ID: KX857137.1	Kenya	99%
–	ID: NG_050326.1	USA	99%
–	ID: KT283238.1	India	99%
–	ID: KM094182.1	Iran	99%
–	ID: HM246150.1	Singapore	99%
–	ID: HM240861.1	Iran: Kerman	99%
–	ID: GQ388247.1	France	99%
–	ID: DQ333895.1	China	99%
–	ID: MG188749.1	Brazil	99%
E. coli	ID: NG055500.1	Thailand	99%
–	ID: NG_050317.1	USA	99%
–	ID: AF205943.1	France	99%
–	ID: AF010416.1	France	99%

Isolate	Accession	Country	Similarity
–	ID: NG_050323.1	Norway	99%
–	ID: NG_050325.1	Thailand	99%

A

Score	Expect	Identities	Gaps	Strand
892 bits (988)	0.0	502/507(99%)	0/507(0%)	Plus/Plus

```
Query 1 TCTTTTGAACAAAAAATAGAGATTACCCCTCAAGACCTTTTGCCTAAAACGTGGAGTCCG 60
   ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct 67 TCTTTTGAACAAAAAATAGAGATTACCCCTCAAGACCTTTTGCCTAAAACGTGGAGTCCG 126
Query 61 ATTAAAGAGGAATTCCCTAATGGAACAACTTTGACGATTGAACAAATACTAAATTATACA 120
   ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct 127 ATTAAAGAGGAATTCCCTAATGGAACAACTTTGACGATTGAACAAATACTAAATTATACA 186
Query 121 GTATCAGAGAGCGACAATATTGGTTGTGATATTTTGCTAAAATTAATCGGAGGAACTGAT 180
   ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct 187 GTATCAGAGAGCGACAATATTGGTTGTGATATTTTGCTAAAATTAATCGGAGGAACTGAT 246
Query 181 TCTGTTCAAAAATTCTTGAATGCTAATCATTTCAGTGATATTTCAATTAAAGCAAACGAA 240
   |||||||||||||||||||||||||||||||||| |||||||||||| ||||||||||||
Sbjct 247 TCTGTTCAAAAATTCTTGAATGCTAATCATTTCACTGATATTTCAATCAAAGCAAACGAA 306
Query 241 GAACAAATGCACAAGGATTGGAATACCCAATATCAAAATTGGGCAACCCCAACAGCGATG 300
   ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct 307 GAACAAATGCACAAGGATTGGAATACCCAATATCAAAATTGGGCAACCCCAACAGCGATG 366
Query 301 AACAAACTGTTAATAGATACTTATAATAATAAGAACCAATTACTTTCTaaaaaaaGTTAT 360
   ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct 367 AACAAACTGTTAATAGATACTTATAATAATAAGAACCAATTACTTTCTAAAAAAAGTTAT 426
Query 361 GATTTTATTTGGAAAATTATGAGAGAAACGACAACAGGAAGTAACCGATTAAAAGGACAA 420
   ||||||||||||||||||||||||||||| ||||||||||||||||||||||||||||||
Sbjct 427 GATTTTATTTGGAAAATTATGAGAGAAACAACAACAGGAAGTAACCGATTAAAAGGACAA 486
Query 421 TTACCAAAGAATACAATTGTTGCTCATAAAACAGGGACTTCCGGAATAAGTAATGGAATT 480
   ||||||||||||||||||||||||||||||||||||||||||||||||| ||||||||||
Sbjct 487 TTACCAAAGAATACAATTGTTGCTCATAAAACAGGGACTTCCGGAATAAATAATGGAATT 546
Query 481 CCAGCAGCCACTAATGATGTTGGGGTA 507
    ||||||||||||||||||||||||||
Sbjct 547 GCAGCAGCCACTAATGATGTTGGGGTA 573
```

B

Score	Expect	Identities	Gaps	Strand
744 bits (824)	0.0	417/420(99%)	0/420(0%)	Plus/Plus

```
Query 1 ATCTTTCTTTTGAACAAAAAATAGAGATTACCCCTCAAGACCTTTTGCCTAAAACGTGGA 60
   ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct 71 ATCTTTCTTTTGAACAAAAAATAGAGATTACCCCTCAAGACCTTTTGCCTAAAACGTGGA 130
Query 61 GTCCGATTAAAGAGGAATTCCCTAATGGAACAACTTTGAGGATTGAACAAATACTAAATT 120
   ||||||||||||||||||||||||||||||||||||||| ||||||||||||||||||||
Sbjct 131 GTCCGATTAAAGAGGAATTCCCTAATGGAACAACTTTGACGATTGAACAAATACTAAATT 190
Query 121 ATACAGTATCAGAGAGCGACAATATTGGTTGTGATATTTTGCTAAAATTAATCGGAGGAA 180
   ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct 191 ATACAGTATCAGAGAGCGACAATATTGGTTGTGATATTTTGCTAAAATTAATCGGAGGAA 250
```

```
Query 181 CTGATTCTGTTCAAAAATTCTTGAATGCTAATCATTTCACTGATATTTCAATCGAAGCAA 240
          ||||||||||||||||||||||||||||||||||||||||||||||||||||| ||||||
Sbjct 251 CTGATTCTGTTCAAAAATTCTTGAATGCTAATCATTTCACTGATATTTCAATCAAAGCAA 310
Query 241 ACGAAGAACAAATGCACAAGGATTGGAATACCGAATATCAAAATTGGGCAACCCCAACAG 300
          |||||||||||||||||||||||||||||||| |||||||||||||||||||||||||||
Sbjct 311 ACGAAGAACAAATGCACAAGGATTGGAATACCCAATATCAAAATTGGGCAACCCCAACAG 370

Query 301 CGATGAACAAACTGTTAATAGATACTTATAATAATAAGAACCAATTACTTTCTaaaaaaa 360
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct 371 CGATGAACAAACTGTTAATAGATACTTATAATAATAAGAACCAATTACTTTCTAAAAAAA 430
Query 361 GTTATGATTTTATTTGGAAAATTATGAGAGAAACAACAACAGGAAGTAACCGATTAAAAG 420
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct 431 GTTATGATTTTATTTGGAAAATTATGAGAGAAACAACAACAGGAAGTAACCGATTAAAAG 490
```

C

Score	Expect	Identities	Gaps	Strand
497 bits (550)	2e-138	278/280(99%)	0/280(0%)	Plus/Plus

```
Query 1 ATTCAACAGCAATGAGAAGGATACTTTGAAGATTAATAACGACTTCCATTTCCCGATGCA 60
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct 141 ATTCAACAGCAATGAGAAGGATACTTTGAAGATTAATAACGACTTCCATTTCCCGATGCA 200
Query 61 AAGCGTTATGAAATTTCCGATTGCTTTAGCCGTTTTGTCTGAGATAGATAAAGGGAATCT 120
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct 201 AAGCGTTATGAAATTTCCGATTGCTTTAGCCGTTTTGTCTGAGATAGATAAAGGGAATCT 260
Query 121 TTCTTTTGAACAAAAAATAGAGATTACCCCTCAAGACCGTTTGCCTAAAACGTGGAGTCC 180
          |||||||||||||||||||||||||||||||||||||| |||||||||||||||||||||
Sbjct 261 TTCTTTTGAACAAAAAATAGAGATTACCCCTCAAGACCTTTTGCCTAAAACGTGGAGTCC 320
Query 181 GATTAAAGAGGAATTCCCTAATGGAACAACTTTGACGATTGAACAAATACTAAATTATAC 240
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct 321 GATTAAAGAGGAATTCCCTAATGGAACAACTTTGACGATTGAACAAATACTAAATTATAC 380
Query 241 AGTATCAGAGACCGACAATATTGGTTGTGATATTTTGCTA 280
          ||||||||||| ||||||||||||||||||||||||||||
Sbjct 381 AGTATCAGAGAGCGACAATATTGGTTGTGATATTTTGCTA 420
```

Fig. (1). Partial sequence of the *bla*$_{VEB}$ genes from the Iraqi (A) *Pseudomonas aeruginosa* isolate (compared with GenBank isolate ID: KT283238.1), (B) *Klebsiella pneumoniae* isolate (compared with GenBank isolate ID: MF417536.1), and (C) *Escherichia coli* isolate (compared with GenBank isolate ID: NG055500.1).

Table 3. VEB gene polymorphisms present in the *Klebsiella pneumonia*, *Pseudomonas aeruginosa*, and *Escherichia coli* isolates relative to the global standard gene.

Accession No.	Nucleotide	Identity	Location	Substitution Type	Source Organism
KM094182.1	**C>G**	99%	**281**	Transversion	***P. aeruginos***
	C>T		**294**	Transition	
	A>G		**456**	Transition	
	A>G		**536**	Transition	
	G>C		**547**	Transversion	
MF417536.1	**C>G**	99%	**170**	Transversion	***K. pneumonia***
	A>G		**304**	Transition	
	C>G		**343**	Transversion	

Accession No.	Nucleotide	Identity	Location	Substitution Type	Source Organism
NG-055500.1	T>G	99%	299	Transversion	*E. coli*
	G>C		392	Transversion	



Fig. (2). Phylogenetic analyses and genetic distances of the Iraqi *Klebsiella pneumonia* (A), *Pseudomonas aeruginosa* (B), and *Escherichia coli* (C) bla_{VEB} gene sequences compared with those of other GenBank isolates.

The bla_{VEB} gene that encoded the *P. aeruginosa* ESBL also demonstrated a genotype closely related to others, deposited in GenBank (Table **2** and Fig. **2**), from India, Iran, France, Brazil, Singapore, Kenya, USA, and China. Similar to the *P. aeruginosa* gene, gene sequencing revealed a 99% similarity with other isolates deposited in GenBank.

Further, the *E. coli* bla_{VEB} gene was closely related to those in isolates from France, USA, Norway, and Thailand and deposited in GenBank (Table **2** and Fig. **2**). Again, gene sequencing revealed 99% compatibility with other Genbank-held genes. Furthermore, sequencing and BLAST analysis of the bla_{VEB} genes isolated from the bacteria in this study showed the types of polymorphisms evident from the global standard genes (Table **3**).

4. DISCUSSION

ESBLs are becoming significant causes of resistance to β-lactam antibiotics, especially in enteric bacteria such as *K. pneumoniae, P. aeruginosa*, and *E. coli*, resulting in severe consequences for the effective treatment of bacterial infections

[13]. In the present study, the CLSI-recommended screening test detected 60 (92.3%) potential ESBL-producing isolates. However, the phenotypic method confirmed ESBL production in only 35 (58.3%) isolates. Ultimately, we were unable to confirm ESBL production in 25 isolates (41.6%). These results are likely due to the presence of other resistance mechanism(s), such as the presence of ambler Class C β-lactamases, as concluded in a previous study [14].

Multiple *K. pneumoniae* isolates were resistant to ceftriaxone (92.3%), ceftazidime (88.4%), aztreonam (80.7%), and cefepime but were generally more sensitive to the Carbapenems tested, similar to the results of Natoubi *et al*. [15]. Others have shown similar percentages of isolates being resistant to ceftazidime, ceftriaxone, and cefepime [16]. In the present study, *K pneumoniae* was the most frequent ESBL producing species, as also observed in another study [17]. However, these results contrast with those of some authors [18 - 20]who showed lower percentages of *K. pneumoniae* isolates being ESBL producers. These differences may be due to different degrees of exposure to β-lactam antibiotics.

Similar to the results obtained by Hakemi *et al*. [21], 34.2% of our *P. aeruginosa* isolates were ESBL-positive. Other authors [22, 23]reported lower rates of ESBL-positive *P. aeruginosa* isolates and one [24] reported a higher rate. These variations in ESBL-positive rates may be related to antibiotic use patterns in different geographic locations as well as differences in infection control procedures for hospital personnel in those regions. Moreover, the spread of ESBL-producing *P. aeruginosa* varies from country to country [22]. In the present study, *Pseudomonas* isolates showed resistance to ceftriaxone (72.4%), ceftazidime (65.5%), aztreonam (24.1%), and one was resistant to imipenem (3.4%), similar to the results by other investigators [22, 25].

Among the *E. coli* isolates included in the present study, high levels of resistance were observed against ceftriaxone (100%), ceftazidime (80%), aztreonam (100%), cefoxitin (90%), meropenem (20%), and imipenem (30%), similar to the rates reported by Hassan *et al*. [26]. In the present study, 14.4% of *E. coli* isolates were ESBL producers, similar to the reported rates of ESBL production in isolates in some studies,[2] but much lower than in other studies [18, 19, 27].

Among the ESBL-producing isolates analyzed in the present study, 3 (8.5%) were carrying the bla_{VEB} gene and 32 (91.4%) were not. This indicated that the majority of the isolates expressed ESBL activity encoded by a different gene, e.g., metallo-β-lactamase enzymes [28]. In this study, the prevalence of bla_{VEB} genes was very low-one isolate in each of the three isolated Gram-negative species produced ESBLs. Among the ESBL-producing *P. aeruginosa* isolates, only 1 (8.5%) possessed the bla_{VEB} gene. In contrast, two other investigations reported the prevalence of bla_{VEB} genes to be 13.3% [29, 30]. In the current study, 1/18 (5.6%) ESBL-producing *K. pneumoniae* isolates possessed the bla_{VEB} gene, whereas other studies have shown the prevalence of bla_{VEB} genes among ESBL-producing *K. pneumoniae* to be 10.6% [31] to 12% [32]. In the present study, the bla_{VEB} gene was present in 1/5 (20%) of ESBL-producing *E. coli* isolates. These results are much different from the results of other studies that showed the prevalence of the bla_{VEB} gene in ESBL-producing *E. coli* to range from 0% [33 - 35] to 8% [36].

The phylogenetic trees of the bla_{VEB} genes isolated in the present study were very similar to those isolated in other countries, with compatibilities of 99%, and showed high similarity with similar isolates from other countries.

CONCLUSION

Carbapenems (imipenem and meropenem) are the best choice for the treatment of ESBL producers of Gram-negative bacterial infections. The bla_{VEB} gene plays an essential role in the resistance of ESBL-producing isolates to new β-lactam antibiotics. Further, the sequencing and phylogenetic analyses of the genes, from the *P. aeruginosa*, *K. pneumonia*, and *E. coli* isolates, revealed 99% similarity with the GenBank global standard genes.

ETHICS APPROVAL AND CONSENT TO PARTICIPATE

Not applicable.

HUMAN AND ANIMAL RIGHTS

No animals/humans were used for studies that are the basis of this research.

CONSENT FOR PUBLICATION

Not applicable.

AVAILABILITY OF DATA AND MATERIALS

The authors confirm that the data supporting the findings of this research are available within the article.

FUNDING

None.

CONFLICT OF INTEREST

The authors declare no conflict of interest, financial or otherwise.

ACKNOWLEDGEMENTS

The authors acknowledge the English language editing assistance of Harkynn Consulting (www.harkynn.com).

REFERENCES

[1] Bush K. Proliferation and significance of clinically relevant β-lactamases. Ann N Y Acad Sci 2013; 1277: 84-90. [http://dx.doi.org/10.1111/nyas.12023]

[2] Rameshkumar G, Ramakrishnan R, Shivkumar C, *et al.* Prevalence and antibacterial resistance patterns of extended-spectrum beta-lactamase producing Gram-negative bacteria isolated from ocular infections. Indian J Ophthalmol 2016; 64(4): 303-11. [http://dx.doi.org/10.4103/0301-4738.182943] [PMID: 27221683]

[3] Nwokah EG, Amala SE. Detection of community-acquired and extended-spectrum β-lactamase-producing uropathogens in a suburban community in rivers state, Nigeria. Eur J Pharm Med Res 2018; 5: 13-7.

[4] Öztürk H, Ozkirimli E, Özgür A. Classification of Beta-lactamases and penicillin binding proteins using ligand-centric network models. PLoS One 2015; 10(2): e0117874. [http://dx.doi.org/10.1371/journal.pone.0117874] [PMID: 25689853]

[5] Akyala AI, Alsam S. Extended spectrum Beta lactamase producing strain of *Salmonella* species - A systematic review. J Microbiol Res

2015; 5: 57-70.
[http://dx.doi.org/10.5923/j.microbiology.20150502.03]

[6] Ur Rahman S, Ali T, Ali I, Khan NA, Han B, Gao J. The growing genetic and functional diversity of extended-spectrum beta-lactamases. BioMed Res Int 2018; 20189519718
[http://dx.doi.org/10.1155/2018/9519718] [PMID: 29780833]

[7] Sengodan T, Kannaiyan M, Sureshkumar BT, Mickymaray S. Antibiotic resistance mechanism of ESBL producing Enterobacteriaceae in clinical field: A review. Int J Pure Appl Biosci 2014; 2: 207-26.

[8] Lahiri SD, Alm RA. Identification of novel VEB β-lactamase enzymes: Impact on avibactam inhibition. Antimicrob Agents Chemother 2016; 60(5): 3183-6.
[http://dx.doi.org/10.1128/AAC.00047-16] [PMID: 26926646]

[9] Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing. 27th ed. Los Angles, CA: Wayne, PA 2017; pp. 1-35.

[10] Baron EJ, Peterson LR, Finegold SM, Bailey S. Diagnosis Microbiology. 9th ed. Toronto, ON: CV Mosby 1994; pp. 85-36.

[11] Sambrook J, Russell DW. Molecular cloning: A laboratory manual. 3rd ed. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press 2001.

[12] Tamura K, Stecher G, Peterson D, Filipski A, Kumar S. Molecular evolutionary genetics analysis version 6.0. Mol Biol Evol 2013; 30: 2725-9.

[13] Abike TO, Olufunke OA, Temitope OO. Prevalence of extended spectrum-lactamases in multidrug-resistant strains of Gram-negative bacteria. Afr J Microbiol Res 2018; 12: 147-51.
[http://dx.doi.org/10.5897/AJMR2017.8755]

[14] Khalaf E A, Al-Ouqaili MTS. Molecular detection and sequencing of SHV gene encoding for extended-spectrum β-lactamases produced by multidrug resistance some of the Gram-negative bacteria. Int J Green Pharm 2018; 12(Suppl.): S910-S918 .

[15] Natoubi S, Barguigua A, Zriouil SB, Baghdad N, Timinouni M, Hilali A, *et al.* Incidence of extended-spectrum beta-lactamase-producing *Klebsiella pneumoniae* among patients and in the environment of Hassan II Hospital, Settat, Morocco. Adv Microbiol 2016; 6: 152-61.
[http://dx.doi.org/10.4236/aim.2016.63015]

[16] Haji HS, Jalal TS, Omer ASH, Mawlood HA. Molecular detection of SHV-Type ESBL in *E. coli* and *K. pneumoniae* and their antimicrobial resistance profile. Zanco Journal of Medical Science 2018; 22: 262-72.
[http://dx.doi.org/10.15218/zjms.2018.035]

[17] Aminzadeh Z, Sadat Kashi M, Sha'bani M. Bacteriuria by extended-spectrum Beta-lactamase-producing *Escherichia coli* and *Klebsiella pneumoniae*: Isolates in a governmental hospital in South of Tehran, Iran. Iran J Kidney Dis 2008; 2(4): 197-200.
[PMID: 19377237]

[18] Rao SP, Rama PS, Gurushanthappa V, Manipura R, Srinivasan K. Extended-spectrum beta-lactamases producing *Escherichia coli* and *Klebsiella pneumoniae*: A multi-centric study across Karnataka. J Lab Physicians 2014; 6(1): 7-13.
[http://dx.doi.org/10.4103/0974-2727.129083] [PMID: 24696553]

[19] Shakya P, Shrestha D, Maharjan E, Sharma VK, Paudyal R. ESBL Production among *E. coli* and *Klebsiella* spp. causing urinary tract infection: A hospital-based study. Open Microbiol J 2017; 11: 23-30.
[http://dx.doi.org/10.2174/1874285801711010023] [PMID: 28553414]

[20] Mahdi Yahya Mohsen S, Hamzah HA, Muhammad Imad Al-Deen M, Baharudin R. Antimicrobial susceptibility of *Klebsiella pneumoniae* and *Escherichia coli* with extended-spectrum β-lactamase associated genes in Hospital Tengku Ampuan Afzan, Kuantan, Pahang. Malays J Med Sci 2016; 23(2): 14-20.
[PMID: 27547110]

[21] Hakemi VM, Hallajzadeh M, Fallah F, Hashemi A, Goudarzi H. Characterization of the extended-spectrum beta-lactamase producers among non-fermenting Gram-negative bacteria isolated from burnt patients. Arch of Hyg Sci 2013; 2: 1-6.

[22] Nithyalakshmi J, Vidhyarani R, Mohanakrishnan K, Sumathi G. ESBL producing *Pseudomonas aeruginosa* in clinical specimens: Is it a scary nightmare or paper tiger? Indian J Microbiol Res 2016; 3: 287-91.
[http://dx.doi.org/10.5958/2394-5478.2016.00062.5]

[23] Shaikh S, Fatima J, Shakil S, Danish Rizvi SM, Kamal MA. Prevalence of multidrug resistant and extended spectrum beta-lactamase producing *Pseudomonas aeruginosa* in a tertiary care hospital. Saudi J Biol Sci 2015; 22(1): 62-4.
[http://dx.doi.org/10.1016/j.sjbs.2014.06.001] [PMID: 25561885]

[24] Mane V, Urekar AD, Insan NG. ESBL, MBL and AMP C detection in multidrug-resistant *Pseudomonas aeruginosa* and pan-drug resistant *Pseudomonas aeruginosa* isolated in tertiary care hospital. Int J Curr Microbiol Appl Sci 2014; 3: 489-92.

[25] Zafer MM, Al-Agamy MH, El-Mahallawy HA, Amin MA, Ashour MS. Antimicrobial resistance pattern and their beta-lactamase encoding genes among *Pseudomonas aeruginosa* strains isolated from cancer patients. BioMed Res Int 2014; 2014101635
[http://dx.doi.org/10.1155/2014/101635] [PMID: 24707471]

[26] Hassan MI, Alkharsah KR, Alzahrani AJ, Obeid OE, Khamis AH, Diab A. Detection of extended spectrum beta-lactamases-producing isolates and effect of AmpC overlapping 2013; 7(8): 1-12.
[http://dx.doi.org/10.3855/jidc.2919]

[27] Devrim F, Serdaroğlu E, Çağlar İ, *et al.* The emerging resistance in nosocomial urinary tract infections: From the pediatrics perspective. Mediterr J Hematol Infect Dis 2018; 10(1)e2018055
[http://dx.doi.org/10.4084/mjhid.2018.055] [PMID: 30210748]

[28] Al-Ouqaili MTS, Al-Taei S, Al-Najjar A. Molecular detection of medically important carbapenemases genes expressed by metallo-β-lactamase producer isolates of *Pseudomonas aeruginosa* and *Klebsiella pneumoniae*. Asian J Pharmaceut 2018; 12(Suppl.): S991-S1001.
[http://dx.doi.org/10.22377/ajp.v12i03.2638]

[29] Amirkamali S, Naserpour-Farivar T, Azarhoosh K, Peymani A. Distribution of the *bla* OXA, *bla* VEB-1, and *bla* GES-1 genes and resistance patterns of ESBL-producing *Pseudomonas aeruginosa* isolated from hospitals in Tehran and Qazvin, Iran. Rev Soc Bras Med Trop 2017; 50(3): 315-20.
[http://dx.doi.org/10.1590/0037-8682-0478-2016] [PMID: 28700048]

[30] Bokaeian M, Zahedani SS, Bajgiran MS, Moghaddam AA. The frequency of PER, VEB, SHV, TEM and CTX-M genes in resistant strains of *Pseudomonas aeruginosa* producing extended spectrum β-lactamases. Jundishapur J Microbiol 2015; 8: e13783.

[31] Latifpour M, Gholipour A, Damavandi MS. Prevalence of extended-spectrum beta-lactamase-producing *Klebsiella pneumoniae* isolates in nosocomial and community-acquired urinary tract infections. Jundishapur J Microbiol 2016; 9(3)e31179
[http://dx.doi.org/10.5812/jjm.31179] [PMID: 27226874]

[32] Sedighi M, Halajzadeh M, Ramazanzadeh R, Amirmozafari N, Heidary M, Pirouzi S. Molecular detection of β-lactamase and integron genes in clinical strains of *Klebsiella pneumoniae* by multiplex polymerase chain reaction. Rev Soc Bras Med Trop 2017; 50(3): 321-8.
[http://dx.doi.org/10.1590/0037-8682-0001-2017] [PMID: 28700049]

[33] Çetinkol Y, Sandalli C, Çalgin MK, Yildirim AA, Akyildiz E, Karaman E, *et al.* High prevalence of NDM metallo-β-lactamase among ESBL-producing *Escherichia coli* isolates. Acta Microbiol Immunol Hung 2017; 64: 131-41.

[34] Zandi K, Jamali H. Isolation of bacterial agents (E. coli) of UTI and phenotypic and genotypic detection of resistant bacteria in hospitals in Jahrom. Palma J 2017; 16: 32-43.

[35] Görgeç S, Kuzucu Ç, Otlu B, Yetkin F, Ersoy Y. Investigation of beta-lactamase genes and clonal relationship among the extended-spectrum beta-lactamase producing nosocomial *Escherichia coli* isolates. Mikrobiyol Bul 2015; 49(1): 15-25.
[http://dx.doi.org/10.5578/mb.8437] [PMID: 25706727]

[36] Rezai MS, Salehifar E, Rafiei A, *et al.* Characterization of multidrug-resistant extended-spectrum beta-lactamase-producing *Escherichia coli* among uropathogens of pediatrics in North of Iran. BioMed Res Int 2015; 6: 1-7.
[http://dx.doi.org/10.1155/2015/309478] [PMID: 26064896]

© 2019 Al-Ouqaili *et al.*

This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: (https://creativecommons.org/licenses/by/4.0/legalcode). This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.